These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 28700265

  • 41. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M.
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [Abstract] [Full Text] [Related]

  • 42. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials.
    Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR.
    Vaccine; 2016 Jul 29; 34(35):4092-4102. PubMed ID: 27381642
    [Abstract] [Full Text] [Related]

  • 43. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.
    Vaccine; 2014 Mar 14; 32(13):1480-7. PubMed ID: 24486352
    [Abstract] [Full Text] [Related]

  • 44. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
    Dunkle LM, Izikson R, Patriarca PA, Goldenthal KL, Muse D, Cox MMJ.
    J Infect Dis; 2017 Dec 05; 216(10):1219-1226. PubMed ID: 28968871
    [Abstract] [Full Text] [Related]

  • 45. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.
    Vesikari T, Nauta J, Lapini G, Montomoli E, van de Witte S.
    Int J Infect Dis; 2020 Mar 05; 92():29-37. PubMed ID: 31838217
    [Abstract] [Full Text] [Related]

  • 46. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study.
    Chang CY, Cho CY, Lai CC, Lu CY, Chang LY, Hung MC, Huang LM, Wu KG.
    Vaccine; 2020 May 08; 38(22):3839-3846. PubMed ID: 32284272
    [Abstract] [Full Text] [Related]

  • 47. Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial.
    Robertson CA, Mercer M, Selmani A, Klein NP, Jeanfreau R, Greenberg DP.
    Pediatr Infect Dis J; 2019 Mar 08; 38(3):323-328. PubMed ID: 30395011
    [Abstract] [Full Text] [Related]

  • 48. Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.
    Gao Y, Yang X, Li X, Chen H, Li Y, Tan X, Yu D, Feng T, Zhou S, Lei S, Zhao C, Wang J, Guan Q.
    Vaccine; 2024 Aug 30; 42(21):126182. PubMed ID: 39116486
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial.
    Hartvickson R, Cruz M, Ervin J, Brandon D, Forleo-Neto E, Dagnew AF, Chandra R, Lindert K, Mateen AA.
    Int J Infect Dis; 2015 Dec 30; 41():65-72. PubMed ID: 26585940
    [Abstract] [Full Text] [Related]

  • 51. Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.
    Choi UY, Kim KH, Lee KY, Kim JH, Kim CS, Eun BW, Kim HM, Kim DH, Song SE, Jo DS, Lee J, Ma SH, Kim KN, Kang JH.
    Vaccine; 2021 Apr 08; 39(15):2103-2109. PubMed ID: 33736920
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial.
    Huang X, Fan T, Li L, Nian X, Zhang J, Gao X, Zhao W, Chen W, Zhang Z, Yao Z, Han X, Shi J, Wang Y, Bian H, Shi N, Li X, Duan K, Li G, Yang X.
    Hum Vaccin Immunother; 2022 Nov 30; 18(5):2079924. PubMed ID: 35714276
    [Abstract] [Full Text] [Related]

  • 54. Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.
    Latreille-Barbier M, Rouzier R, Astruc B, Lavis N, Donazzolo Y.
    Hum Vaccin Immunother; 2017 Nov 02; 13(11):2674-2677. PubMed ID: 28937844
    [Abstract] [Full Text] [Related]

  • 55. Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial.
    Wang Y, Zhang Y, Wu H, Huang L, Yu H, Xie Z, Zhang H, Zhang W, Chen X, Zhang H, Zhang H, Jia C, Xia S, Wang S.
    Vaccine; 2021 Jun 29; 39(29):3871-3878. PubMed ID: 34088505
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Essink B, Fierro C, Rosen J, Figueroa AL, Zhang B, Verhoeven C, Edelman J, Smolenov I.
    Vaccine; 2020 Jan 10; 38(2):242-250. PubMed ID: 31635976
    [Abstract] [Full Text] [Related]

  • 58. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.
    Vaccine; 2011 Nov 21; 29(50):9391-7. PubMed ID: 21983154
    [Abstract] [Full Text] [Related]

  • 59. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    J Infect Dis; 2013 Jun 15; 207(12):1878-87. PubMed ID: 23470848
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.